DoubleTwist Signs On Merck, Postpones IPO | GenomeWeb

DoubleTwist has licensed its annotated human genome database package to Merck, the first major pharmaceutical company to publicly sign on for the company’s database.

Under the terms of the two-year deal, Merck and seven of its affiliates will use DoubleTwist’s Prophecy annotated human genome database in their drug discovery efforts.

The deal also includes access to software for data interpretation and visualization.

Financial terms of the deal were not disclosed. Merck did not return calls seeking comment about the decision to subscribe to Prophecy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.